Am 10.07.2023, 15:01 Uhr notiert die Aktie Exicure an ihrem Heimatmarkt NASDAQ CM mit dem Kurs von 1.062 USD. Das Unternehmen gehört zum Segment "Biotechnologie". Auf Basis von insgesamt 4 ...
Exicure, ein Unternehmen aus dem Markt "Biotechnologie", notiert aktuell (Stand 19:28 Uhr) mit 1.44 USD stark im Plus (+1.39 Prozent), die Heimatbörse des Unternehmens ist NASDAQ CM. Unsere Analysten ...
Exicure, Inc. (NADAQ:XCUR) stock is trading higher on Monday after the company entered into debt-for-equity exchange agreements. What Happened: On Friday, Exicure filed a Form 8-K with the Securities ...
CHICAGO, IL – Exicure, Inc. (NASDAQ:XCUR), ein auf die Entwicklung von Behandlungen spezialisiertes Pharmaunternehmen, gab heute bekannt, dass es vom Nasdaq Hearings Panel eine Fristverlängerung für ...
REDWOOD CITY, Calif., August 04, 2025--(BUSINESS WIRE)--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic ...
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ...
REDWOOD CITY, Calif., May 28, 2025--(BUSINESS WIRE)--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ...
Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase 2 multiple myeloma trial, paving the way for smoother and more effective ...
Exicure, Inc., a clinical-stage biotechnology company developing therapeutics for hematologic diseases, announced it has completed the last patient, last visit in its ongoing phase 2 clinical trial ...
Exicure, Inc., an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, is planning for a clinical trial in acute myeloid ...
Exicure, Inc. (NASDAQ:XCUR) gab am Donnerstag bekannt, dass der erste Meilenstein im Rahmen der Lizenz- und Kooperationsvereinbarung mit GPCR Therapeutics Inc. erreicht wurde. Der Meilenstein wurde ...
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc. (OTC:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results